SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Although some emerging drugs such as sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown benefits for NAFLD (4), approved pharmacotherapy for NAFLD is lacking.